Surgery Partners

SGRY on Nasdaq. Surgery Partners sells surgical care at outpatient facilities to patients and physicians. Market value $1.7bn.

Watch this stockFree. We tell you when something changes.

Price checks use the past 12 months to June 2026. Quality checks use five annual reports, the latest for the year to December 2025.

Should I look at this?

Worth a closer look

Read what could go wrong

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
past 12 months to June 2026
10.7%very high

For every $100 of what the whole company costs, it produced $10.69 of spare cash in the past 12 months. A savings account pays about $4.

Price to profit
past 12 months to June 2026
13.8×fair

You pay 13.8 years of operating profit for the business. The average large US company costs around 18.

Return on capital
five annual reports to December 2025
5.9%five-year median

Each dollar kept in the business earns 6 cents a year. Above 10 is good.

Quality score: 72 of 100. Price score: 63 of 100. Our list needs 70 on quality and 60 on price.

$13.41 a share, 18% above its 1-year low

Over the past year the price has ranged from $11.41 to $23.44.

Pays no dividend

Prices from Tuesday’s close (6 October).

Five years of cash, in billions

0.0
0.1
0.2
0.2
0.2
0.2
2021202220232024202512 monthsto Jun '26
Revenue
$2.2bn$2.5bn$2.7bn$3.1bn$3.3bn
Operating margin
13.6%13.6%12.0%11.2%11.8%
Debt to equity
2.701.311.401.882.16
Shares outstanding
0.09bn0.13bn0.13bn0.13bn0.13bn

Health checks

  • Free cash flow positive5 of 5 years
  • Accounting looks honest (Beneish)Not enough data
  • Financial strength (Piotroski)4 of 8 checks we could run
  • Profit backed by cash (accruals)Yes
  • Debt2.16× equity
  • Revenue growth, five yearsStrong, 12.2% a year
  • Buying back its own sharesNo, 46% more shares since 2021

The quarter to June 2026

How the business did, compared with the same quarter a year earlier.

  • Sales: $849 million last quarter, up 3% on a year ago.
  • A loss of $15 million, compared with a loss of $3 million a year ago.
  • It keeps 11 cents of each $1 of sales as operating profit, about the same as a year earlier.
  • Spare cash over the past 12 months: $188 million, up from $175 million.
  • 1% more shares than a year ago. Each share owns a bit less of the company.
  • Debt is $3.5 billion more than cash, up from $3.3 billion a year ago.
  • Sales grew on a year ago in each of the last 4 quarters.
Sales by quarter
Sales by quarter
Quarter toAmount
September 2024$770m
December 2024$864m
March 2025$776m
June 2025$826m
September 2025$822m
December 2025$885m
March 2026$811m
June 2026$849m
Profit by quarter
Profit by quarter
Quarter toAmount
September 2024-$32m
December 2024-$109m
March 2025-$38m
June 2025-$3m
September 2025-$23m
December 2025-$15m
March 2026-$36m
June 2026-$15m

From the company's quarterly reports to the SEC.

Dates

Next results (estimated)
n/a
Last annual report (10-K)
2 March 2026
Next quarterly (estimated, 10-Q)
9 November 2026

Who owns it

1 long-term investor we follow owns it, down from 2 last quarter. 187 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

5 investors own more than 5%.

  • BCPE Seminole Holdings II Intermediate, LP
    Strategic holder
    at least 23.4%−0.1 pts
    (filed with 3 related holders)
    Since 16 June 2025
    What they said

    Item 4 of the Initial Statement is hereby amended and supplemented by adding the following at the end of Item 4 of the Initial Statement: On the evening of January 27, 2025, Bain Capital Private Equity, LP, the investment advisor to funds invested through the Reporting Persons,…

    Read the filing
  • at least 10.2%+0.1 pts
    (filed with 1 related holder)
    Since 30 September 2025
  • at least 9.7%+2.0 pts
    (filed with 1 related holder)
    Since 31 March 2026
  • Wellington Management Company LLP
    Passive investor
    5.4%
    Since 31 March 2025
  • at least 4.6%−2.6 pts
    (filed with 2 related holders)
    Since 30 June 2026
  • BlackRock, Inc.
    Passive investor
    Sold down below 5%
    Since 31 March 2025
  • FMR LLC
    Passive investor
    Sold down below 5%
    Since 31 March 2026
  • The Vanguard Group
    Passive investor
    Sold down below 5%
    Since 13 March 2026
  • Sold down below 5%
    Since 30 June 2025

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

In the last 12 months, 1 insider bought $161,213 of shares on the open market. 6 sold $1m.

  • DeLuca Teresa
    Director
    Bought
    Date
    18 August 2026
    Shares
    11,250
    Price
    $14.33
    Value
    $161,213
  • Doherty David T
    Chief Financial Officer
    Sold
    Date
    16 March 2026
    Shares
    8,867
    Price
    $12.50
    Value
    $110,838
  • Evans Jason Eric
    Chief Executive Officer
    Sold
    Date
    16 March 2026
    Shares
    20,400
    Price
    $12.47
    Value
    $254,388
  • Burkhalter Danielle
    Chief Human Resources Officer
    Sold
    Date
    13 March 2026
    Shares
    3,469
    Price
    $12.83
    Value
    $44,507
  • Brittenham Marissa
    Chief Strategy Officer
    Sold
    Date
    13 March 2026
    Shares
    3,657
    Price
    $12.54
    Value
    $45,859
  • Baldock Jennifer
    Chief Admin & Dev Officer
    Sold
    Date
    12 March 2026
    Shares
    5,798
    Price
    $13.17
    Value
    $76,360
  • Evans Jason Eric
    Chief Executive Officer
    Sold
    Date
    6 March 2026
    Shares
    11,462
    Price
    $13.79
    Value
    $158,061
  • Doherty David T
    Chief Financial Officer
    Sold
    Date
    6 March 2026
    Shares
    14,574
    Price
    $13.84
    Value
    $201,704
  • Baldock Jennifer
    Chief Admin & Dev Officer
    Sold
    Date
    6 March 2026
    Shares
    10,082
    Price
    $13.70
    Value
    $138,123
  • Burkhalter Danielle
    Chief Human Resources Officer
    Sold
    Date
    6 March 2026
    Shares
    7,736
    Price
    $13.60
    Value
    $105,210

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

None of the warning signs we check for were found.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 2 Mar 2026, plus the 10-Q filed 10 Aug 2026 and 5 later 8-Ks.

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

What could go wrong

  • It carries a lot of debt: 2.2× its equity.

Whether the price already reflects the risks is what the deep dive is for.

What changed in the risks this year

Companies must list what could hurt them each year. These are the parts that changed since last year’s report.

  • We cannot predict the effect that changes in healthcare laws, regulations, policies and government programs may have on our business, financial condition or results of operations.

    Could happen
    Over the past several years, various laws and regulations lengthened the enrollment period, expanded income eligibility, and reduced premium caps for subsidies for individuals purchasing Affordable Care Act coverage through state and federal marketplaces. However, several of these provisions – notably, those relating to premium caps for subsidies – expired on December 31, 2025. The failure of Congress to renew these subsidies through legislative action is widely anticipated to result in significant increases in premiums, potentially leading to decreased enrollment and a corresponding rise in the number of uninsured individuals or a shift of individuals from commercial coverage to government program coverage in 2026. As a direct effect of these changes, the Company may experience decreased patient volumes, reduced revenues and an increase in uncompensated care, which would adversely affect the Company’s results of operations and cash flows. We cannot predict whether or how the Congress may further extend (or decline to extend) or modify provisions of or relating to the Affordable Care Act or other laws affecting the healthcare industry generally, nor can we predict how the current administration will influence, promulgate or implement rules, regulations or executive orders that affect the healthcare industry directly or indirectly (including, for example, through changes resulting from the provisions of the OBBBA). We may also experience potential impacts on our business, in ways we cannot anticipate, from healthcare-related policy changes at the state level. Some federal and state changes, initiatives and requirements could, among other things, negatively impact our patient volumes, case mix and revenue mix, increase our operating costs, adversely affect the reimbursement we receive for our services, impact our competitive position or require us to expend resources to modify certain aspects of our operations, any of which could have an adverse effect on our financial condition, results of operations or cash flows. Furthermore, we cannot predict the impact healthcare policy risks and uncertainties may have on the trading price of our common stock.
    Read more

Read it in the annual report

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.